<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.114257</article-id><article-id pub-id-type="publisher-id">ACM-41826</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210400000_83898262.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  冠心宁对不稳定型心绞痛患者心肺功能保护作用的研究
  Study on the Protective Effect of Guanxinning on the Cardiopulmonary Function of Patients with Unstable Angina Pectoris
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>唐</surname><given-names>伟良</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郑</surname><given-names>招海</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>鹏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>沈</surname><given-names>静</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>妍</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>彭</surname><given-names>放</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>绍兴市人民医院(浙江大学绍兴医院)心内科，浙江 绍兴</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>1157</fpage><lpage>1163</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探索冠心宁片对不稳定型心绞痛患者心肺功能的保护作用及其可能涉及的相关机制。方法：选取2019年6月至2020年5月我院80例因不稳定型心绞痛入院，拟行择期冠脉介入(PCI)治疗的患者，随机分为对照组和干预组。对照组术前行常规抗凝及调脂治疗，干预组在常规治疗基础上辅以冠心宁片4片每日三次治疗3个月。住院期间监测患者心律失常、心绞痛的发作频率；收集患者入院时、PCI术后及3个月后心功能指标：左心射血分数(LVEF)、肌酸激酶同工酶(CK-MB)、肌钙蛋白(cTnT)、超敏C反应蛋白(hs-CRP)、B型脑钠肽(BNP)及肾功能指标：肾小球滤过率(eGFR)、肌酐(SCr)；出院前及3个月后行6分钟步行试验、心肺运动试验。结果：冠心宁组患者心律失常、心绞痛等事件发生频率低于对照组(P &lt; 0.05)。PCI术后及治疗3个月后，两组心功能指标均较治疗前改善，且冠心宁组的改善程度优于对照组(P &lt; 0.05)。PCI术后，两组患者肾功能下降，但冠心宁组患者肾功能损害程度小于对照组(P &lt; 0.05)，治疗3个月后，冠心宁组患者肾功能改善程度优于对照组(P &lt; 0.01)。此外，治疗3月后两组患者6分钟步行距离、最大摄氧量(VO2max)、无氧阈值(AT)、代谢当量(MET)等心肺功能指标均有明显改善(P &lt; 0.05)，且冠心宁组的改善程度均优于对照组(P &lt; 0.01)。结论：冠心宁片干预不稳定型心绞痛患者，有助于：1) 减少患者心绞痛、心律失常等不良心血管事件；2) 改善LVEF、6分钟步行距离、VO2max、AT及MET等指标，提高患者的心肺运动功能；3) 改善肾功能，降低PCI术后对比剂带来的肾功能损害；4) 降低CK-MB、cTnT、hs-CRP等，改善机体炎症反应。项目研究结果提示，冠心宁的上述保护作用可能是通过改善组织的血液循环、降低氧化应激和炎症反应等机制而实现的。
    Objective: To explore the protective effect of Guanxining Tablet on cardiopulmonary function in patients with unstable angina pectoris and its possible related mechanisms. Methods: Eighty patients with unstable angina pectoris who were admitted to our hospital from June 2019 to May 2020 and planned to undergo elective coronary intervention (PCI) were randomly divided into control group and intervention group. The control group received routine anticoagulation and lipid-regulating treatment before PCI, while the intervention group was additively treated with 4 Guanxining tablets three times a day for 3 months. The attack frequency of arrhythmia and angina pectoris was monitored during hospitalization. Cardiac function indexes at admission, after PCI and 3 months after PCI were collected, including left cardiac ejection fraction (LFEF), creatine kinase isoenzyme (CK-MB), troponin (cTnT), hypersensitive C-reactive protein (hs-CRP), B-type brain natriuretic peptide (BNP), and renal function indexes: glomerular filtration rate (EGFR), creatinine (SCR). The 6-minute walking test and cardiopulmonary exercise test were performed before discharge and 3 months after discharge. Results: The frequency of arrhythmia and angina pectoris in Guanxining group was lower than that in control group (P &lt; 0.05). After PCI and treatment of 3 months, the heart function indexes in both groups were improved compared with those before treatment (P &lt; 0.05), and the improvement in the Guanxinning group was bigger than that in the control group (P &lt; 0.05). After PCI, renal function of both groups was decreased (P &lt; 0.05), but the Guanxinning group of patients with renal damage was much less than the control group (P &lt; 0.05), after 3 months of treatment, renal function indexes of two groups were improved (P &lt; 0.05), and the improvement of the Guanxinning group is higher than that of control group (P &lt; 0.01). After 3 months of treatment, cardiopulmonary function indexes, such as 6-minute walking distance, VO2max, anaerobic threshold (AT), metabolic equivalent (MET) were significantly improved in the control group and Guanxinning group (P &lt; 0.05), and the improvement degree in the Guanxinning group was better than that in the control group (P &lt; 0.01). Conclusion: This study found that the intervention of Guanxining Tablet is helpful to: 1) Reduce the occurrence of adverse cardiovascular events such as angina pectoris and arrhythmia in patients with unstable angina pectoris; 2) Improve the indexes such as LVEF, 6-minute walking distance, VO2max, AT and MET to improve the cardiopulmonary motor function of patients; 3) Improve renal function and reduce renal function damage caused by contrast agents after PCI; 4) Reduce the level of CK-MB, cTnT, hs-CRP, etc., and improve the inflammatory response of the body. The results of this study suggest that the protective effects of Guanxinning may be achieved by improving blood circulation, reducing oxidative stress and inflammatory response. 
  
 
</p></abstract><kwd-group><kwd>冠心宁，不稳定型心绞痛，心肺功能，六分钟步行试验，对比剂肾病, Guanxinning</kwd><kwd> Unstable Angina</kwd><kwd> Cardiopulmonary Function</kwd><kwd> Six-Minute Walk Test</kwd><kwd> Contrast Induced Nephropathy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探索冠心宁片对不稳定型心绞痛患者心肺功能的保护作用及其可能涉及的相关机制。方法：选取2019年6月至2020年5月我院80例因不稳定型心绞痛入院，拟行择期冠脉介入(PCI)治疗的患者，随机分为对照组和干预组。对照组术前行常规抗凝及调脂治疗，干预组在常规治疗基础上辅以冠心宁片4片每日三次治疗3个月。住院期间监测患者心律失常、心绞痛的发作频率；收集患者入院时、PCI术后及3个月后心功能指标：左心射血分数(LVEF)、肌酸激酶同工酶(CK-MB)、肌钙蛋白(cTnT)、超敏C反应蛋白(hs-CRP)、B型脑钠肽(BNP)及肾功能指标：肾小球滤过率(eGFR)、肌酐(SCr)；出院前及3个月后行6分钟步行试验、心肺运动试验。结果：冠心宁组患者心律失常、心绞痛等事件发生频率低于对照组(P &lt; 0.05)。PCI术后及治疗3个月后，两组心功能指标均较治疗前改善，且冠心宁组的改善程度优于对照组(P &lt; 0.05)。PCI术后，两组患者肾功能下降，但冠心宁组患者肾功能损害程度小于对照组(P &lt; 0.05)，治疗3个月后，冠心宁组患者肾功能改善程度优于对照组(P &lt; 0.01)。此外，治疗3月后两组患者6分钟步行距离、最大摄氧量(VO<sub>2</sub>max)、无氧阈值(AT)、代谢当量(MET)等心肺功能指标均有明显改善(P &lt; 0.05)，且冠心宁组的改善程度均优于对照组(P &lt; 0.01)。结论：冠心宁片干预不稳定型心绞痛患者，有助于：1) 减少患者心绞痛、心律失常等不良心血管事件；2) 改善LVEF、6分钟步行距离、VO<sub>2</sub>max、AT及MET等指标，提高患者的心肺运动功能；3) 改善肾功能，降低PCI术后对比剂带来的肾功能损害；4) 降低CK-MB、cTnT、hs-CRP等，改善机体炎症反应。项目研究结果提示，冠心宁的上述保护作用可能是通过改善组织的血液循环、降低氧化应激和炎症反应等机制而实现的。</p></sec><sec id="s2"><title>关键词</title><p>冠心宁，不稳定型心绞痛，心肺功能，六分钟步行试验，对比剂肾病</p></sec><sec id="s3"><title>Study on the Protective Effect of Guanxinning on the Cardiopulmonary Function of Patients with Unstable Angina Pectoris<sup> </sup></title><p>Weiliang Tang, Zhaohai Zhen, Peng Zhang, Jing Shen, Yan Zhou, Fang Peng<sup>*</sup></p><p>Shaoxing People’s Hospital, Shaoxing Zhejiang</p><p><img src="//html.hanspub.org/file/50-1572177x5_hanspub.png" /></p><p>Received: Mar. 19<sup>th</sup>, 2021; accepted: Apr. 18<sup>th</sup>, 2021; published: Apr. 25<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/50-1572177x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the protective effect of Guanxining Tablet on cardiopulmonary function in patients with unstable angina pectoris and its possible related mechanisms. Methods: Eighty patients with unstable angina pectoris who were admitted to our hospital from June 2019 to May 2020 and planned to undergo elective coronary intervention (PCI) were randomly divided into control group and intervention group. The control group received routine anticoagulation and lipid-regulating treatment before PCI, while the intervention group was additively treated with 4 Guanxining tablets three times a day for 3 months. The attack frequency of arrhythmia and angina pectoris was monitored during hospitalization. Cardiac function indexes at admission, after PCI and 3 months after PCI were collected, including left cardiac ejection fraction (LFEF), creatine kinase isoenzyme (CK-MB), troponin (cTnT), hypersensitive C-reactive protein (hs-CRP), B-type brain natriuretic peptide (BNP), and renal function indexes: glomerular filtration rate (EGFR), creatinine (SCR). The 6-minute walking test and cardiopulmonary exercise test were performed before discharge and 3 months after discharge. Results: The frequency of arrhythmia and angina pectoris in Guanxining group was lower than that in control group (P &lt; 0.05). After PCI and treatment of 3 months, the heart function indexes in both groups were improved compared with those before treatment (P &lt; 0.05), and the improvement in the Guanxinning group was bigger than that in the control group (P &lt; 0.05). After PCI, renal function of both groups was decreased (P &lt; 0.05), but the Guanxinning group of patients with renal damage was much less than the control group (P &lt; 0.05), after 3 months of treatment, renal function indexes of two groups were improved (P &lt; 0.05), and the improvement of the Guanxinning group is higher than that of control group (P &lt; 0.01). After 3 months of treatment, cardiopulmonary function indexes, such as 6-minute walking distance, VO<sub>2</sub>max, anaerobic threshold (AT), metabolic equivalent (MET) were significantly improved in the control group and Guanxinning group (P &lt; 0.05), and the improvement degree in the Guanxinning group was better than that in the control group (P &lt; 0.01). Conclusion: This study found that the intervention of Guanxining Tablet is helpful to: 1) Reduce the occurrence of adverse cardiovascular events such as angina pectoris and arrhythmia in patients with unstable angina pectoris; 2) Improve the indexes such as LVEF, 6-minute walking distance, VO<sub>2</sub>max, AT and MET to improve the cardiopulmonary motor function of patients; 3) Improve renal function and reduce renal function damage caused by contrast agents after PCI; 4) Reduce the level of CK-MB, cTnT, hs-CRP, etc., and improve the inflammatory response of the body. The results of this study suggest that the protective effects of Guanxinning may be achieved by improving blood circulation, reducing oxidative stress and inflammatory response.</p><p>Keywords:Guanxinning, Unstable Angina, Cardiopulmonary Function, Six-Minute Walk Test, Contrast Induced Nephropathy</p><disp-formula id="hanspub.41826-formula29"><graphic xlink:href="//html.hanspub.org/file/50-1572177x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/50-1572177x8_hanspub.png" /> <img src="//html.hanspub.org/file/50-1572177x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>不稳定型心绞痛(unstable angina, UA)是以冠状动脉粥样硬化斑块不稳定为基本的病理生理特点，是急性冠状动脉综合征(acute coronary syndrome，ACS)中一种复杂的动态综合征，以心绞痛为典型症状，易发展为急性心肌梗死甚至猝死，病死率高。及时有效的冠状动脉再灌注治疗，如经皮冠状动脉介入术(percutaneous coronary intervention, PCI)的广泛开展，恢复心肌血运重建，为临床公认的治疗ACS降低临床病死率的有效方法。然而，PCI术后无复流、急性血栓形成及栓塞所致心律失常、心绞痛等不良心血管事件的发生率仍较高，增加了临床再发心梗的风险 [<xref ref-type="bibr" rid="hanspub.41826-ref1">1</xref>] ，也对改善患者心肺功能产生了明显的影响。在当前临床规范治疗的基础上，探索祖国医学对UA患者预后的改善作用，成为一种迫切的临床需求，而冠心宁片可能是实现这一需求的合理途径。</p><p>冠心宁主要成分为丹参和川芎，具有活血化瘀、通脉养心的功效，临床上用于冠心病、心绞痛、心肌梗死等心血管疾病的治疗 [<xref ref-type="bibr" rid="hanspub.41826-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.41826-ref3">3</xref>]。现代药理学研究证实，丹参具有活血化瘀、扩张血管、增加冠状动脉血流量、降低外周血管阻力、减少心肌耗氧和促进侧支循环等作用；川芎具有通脉养心、改善血流变及微循环、降血脂、抑制炎症反应、抗血栓形成等作用。上述两种有效成分互相促进，可同时抑制血小板聚集及炎症激活，促使斑块稳定，减少冠心病事件。进一步研究还表明 [<xref ref-type="bibr" rid="hanspub.41826-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.41826-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.41826-ref6">6</xref>] ，冠心宁可通过抑制血小板聚集、改善冠脉微循环、抗氧化以及维持心血管功能稳态等机制实现对心肌缺血的保护作用。心肌缺血的改善，对于因缺血带来的心肺功能下降也有着积极的保护作用。因此，本研究使用冠心宁片干预UA患者，旨在探索冠心宁对UA患者择期PCI术后心肺功能的影响，为临床治疗提供客观依据。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 病例选择</title><p>选取2019年6月至2020年5月我院80例因不稳定型心绞痛入院，拟行择期PCI治疗的患者，按照入院顺序作为编号，依据随机数字表法分为对照组(n = 40)和干预组(n = 40)。项目伦理审查经绍兴市人民医院伦理审查委员会审批通过(批号：2019-K-Y-093-01)。</p></sec><sec id="s6_2"><title>2.2. 研究方法</title><p>对照组术前行常规抗凝及调脂治疗，干预组在常规治疗基础上辅以冠心宁片(正大青春宝药业有限公司，批号：1909001) 4片tid治疗。随访3个月。</p><p>1) 监测住院期间患者心律失常、心绞痛的发作频率：住院期间心电监护密切监测两组患者心律失常、心绞痛等不良心血管事件的发生。</p><p>2) 检测患者入院时、PCI术后及随访3个月后心肾功能指标：左心室射血分数(Left ventricular ejection fraction, LVEF)、肌酸激酶同工酶(Creatine kinase isoenzyme, CK-MB)、心肌肌钙蛋白T (Cardiac troponin T, cTnT)、高敏C反应蛋白(High sensitivity C-reactive protein, hs-CRP)、B型脑钠肽(B-type brain natriuretic peptide, BNP)、估算肾小球滤过率(Estimated glomerular filtration rate, eGFR)、血清肌酐(Serum creatinine, SCr)：</p><p>检测患者心功能指标：床边心脏超声检测LVEF，抽取空腹静脉血5 ml，使用本院自动生化分析仪检测CK-MB、cTnT、hs-CRP、BNP水平。</p><p>检测患者肾功能指标：抽取空腹静脉血5 ml，使用本院自动生化分析仪测定eGFR、SCr水平。</p><p>3) 患者出院前及随访3个月后行6分钟步行试验、心肺运动试验：</p><p>6分钟步行试验：试验前患者在起点旁坐椅子休息至少10 min，准备相关抢救药物及设备，测量脉搏，血压，血氧饱和饱和度，核查有无禁忌证(绝对禁忌证：近1个月内出现的不稳定型心绞痛或心肌梗死；相对禁忌证：静息心率 &gt; 120/min，收缩压 &gt; 180 mmHg和舒张压 &gt; 100 mmHg)。让患者站起，用Borg分级评价患者运动前呼吸困难和全身疲劳情况，计时器设定到6 min，让患者在室内封闭的地面平直走廊上快步行走，结束时标记好停止的地点。如患者出现胸痛、难以忍受的呼吸困难、下肢痉挛、步履蹒跚、出汗、面色苍白等症状需提前终止试验，使患者立即休息并记录提前终止的地点、时间和原因。试验结束后统计患者总步行距离，精确到米，监测并记录患者血压、心率，血氧饱和饱和度，再次用Borg分级评价患者的呼吸困难和全身疲劳情况。</p><p>心肺运动试验：试验开始前评估患者有无禁忌症，确定终止指标，和相关抢救药物及设备，对测量设备定标，使患者佩戴设备，开始运动负荷测试，测试分为静息、空蹬、负荷递增、恢复四个阶段，测试期间密切关注患者心率、心电图、血压及血氧饱和度等参数，了解患者自我感觉及疲劳程度，是否出现心电异常及需要终止试验的情况。观察最大摄氧量(VO<sub>2</sub>max)、无氧阈值(Anaerobic threshold, AT)、代谢当量(Metabolic equivalent, MET)等主要参数。</p></sec><sec id="s6_3"><title>2.3. 统计学方法</title><p>采用SPSS 22.0统计软件进行统计分析，计量资料以均数&#177;标准差( x &#175; &#177; s )表示，组间计量资料比较采用成组t检验；两组计数资料比较采用χ<sup>2</sup>检验。P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 研究结果</title><sec id="s7_1"><title>3.1. 一般资料比较</title><p>两组患者一般资料比较见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of general data between the two groups[n(%)</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  colspan="2"  >性别</th><th align="center" valign="middle"  rowspan="2"  >年龄{岁，( x &#175; &#177; s )}</th></tr></thead><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >女</td></tr><tr><td align="center" valign="middle" >对照组(N = 40)</td><td align="center" valign="middle" >23 (57.5)</td><td align="center" valign="middle" >17 (52.5)</td><td align="center" valign="middle" >54.1 &#177; 15.7</td></tr><tr><td align="center" valign="middle" >冠心宁组(N = 40)</td><td align="center" valign="middle" >18 (45)</td><td align="center" valign="middle" >22 (55)</td><td align="center" valign="middle" >52.6 &#177; 14.5</td></tr></tbody></table></table-wrap><p>表1. 两组患者的一般资料比较[n(%)]</p></sec><sec id="s7_2"><title>3.2. 两组患者住院期间心律失常、心绞痛发作频率</title><p>冠心宁组心律失常、心绞痛等不良心血管事件发生频率明显低于对照组(P &lt; 0.05)。见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Frequency of arrhythmia and angina pectoris in the two groups during hospitalization( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >对照组(N = 40)</th><th align="center" valign="middle" >冠心宁组(N = 40)</th></tr></thead><tr><td align="center" valign="middle" >心律失常发作频率(次)</td><td align="center" valign="middle" >10.5 &#177; 1.7</td><td align="center" valign="middle" >7.1 &#177; 1.5*</td></tr><tr><td align="center" valign="middle" >心绞痛发作频率(次)</td><td align="center" valign="middle" >8.9 &#177; 1.6</td><td align="center" valign="middle" >6.3 &#177; 1.3*</td></tr></tbody></table></table-wrap><p>表2. 两组住院期间心律失常、心绞痛发作频率( x &#175; &#177; s )</p><p>注：*，与对照组相较，P &lt; 0.05。</p></sec><sec id="s7_3"><title>3.3. 两组患者入院前、PCI术后、3个月后心功能指标比较</title><p>对照组与冠心宁组入院前心功能指标均无显著性差异(P &gt; 0.05)，PCI术后及治疗3个月后，两组心功能指标均较治疗前改善(P &lt; 0.05)，且冠心宁组的改善程度均优于对照组(P &lt; 0.05)，差异具有统计学意义。见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of cardiac function between the two groups before admission, after PCI and 3 months later ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  colspan="3"  >对照组(N = 40)</th><th align="center" valign="middle"  colspan="3"  >冠心宁组(N = 40)</th></tr></thead><tr><td align="center" valign="middle" >入院时</td><td align="center" valign="middle" >PCI术后</td><td align="center" valign="middle" >3个月后</td><td align="center" valign="middle" >入院时</td><td align="center" valign="middle" >PCI术后</td><td align="center" valign="middle" >3个月后</td></tr><tr><td align="center" valign="middle" >LVEF (%)</td><td align="center" valign="middle" >55.64 &#177; 7.56</td><td align="center" valign="middle" >56.46 &#177; 6.79<sup>a</sup></td><td align="center" valign="middle" >57.24 &#177; 6.75<sup>a</sup></td><td align="center" valign="middle" >54.92 &#177; 7.34</td><td align="center" valign="middle" >58.57 &#177; 7.44<sup>b</sup></td><td align="center" valign="middle" >59.34 &#177; 7.01<sup>b#</sup></td></tr><tr><td align="center" valign="middle" >CK-MB (U/L)</td><td align="center" valign="middle" >20.43 &#177; 7.68</td><td align="center" valign="middle" >12.14 &#177; 5.54<sup>a</sup></td><td align="center" valign="middle" >10.28 &#177; 4.41<sup>a</sup></td><td align="center" valign="middle" >20.56 &#177; 7.84</td><td align="center" valign="middle" >10.24 &#177; 4.16<sup>b</sup></td><td align="center" valign="middle" >6.26 &#177; 2.21<sup>b#</sup></td></tr><tr><td align="center" valign="middle" >c-TnT (mg/L)</td><td align="center" valign="middle" >0.81 &#177; 0.18</td><td align="center" valign="middle" >0.58 &#177; 0.11<sup>a</sup></td><td align="center" valign="middle" >0.49 &#177; 0.10<sup>a</sup></td><td align="center" valign="middle" >0.79 &#177; 0.21</td><td align="center" valign="middle" >0.47 &#177; 0.08<sup>b</sup></td><td align="center" valign="middle" >0.31 &#177; 0.06<sup>b#</sup></td></tr><tr><td align="center" valign="middle" >hs-CRP (mg/L)</td><td align="center" valign="middle" >8.45 &#177; 2.42</td><td align="center" valign="middle" >4.36 &#177; 1.16<sup>a</sup></td><td align="center" valign="middle" >3.27 &#177; 1.25<sup>a</sup></td><td align="center" valign="middle" >8.67 &#177; 3.20</td><td align="center" valign="middle" >3.85 &#177; 1.15<sup>b</sup></td><td align="center" valign="middle" >2.01 &#177; 1.13<sup>b#</sup></td></tr><tr><td align="center" valign="middle" >BNP (mg/L)</td><td align="center" valign="middle" >614.41 &#177; 180.35</td><td align="center" valign="middle" >220.48 &#177; 65.03<sup>a</sup></td><td align="center" valign="middle" >201.56 &#177; 43..29<sup>a</sup></td><td align="center" valign="middle" >613.45 &#177; 180.03</td><td align="center" valign="middle" >125.55 &#177; 23.85<sup>b</sup></td><td align="center" valign="middle" >110.53 &#177; 20.57<sup>b#</sup></td></tr></tbody></table></table-wrap><p>表3. 两组入院前、PCI术后、3个月后心功能指标比较( x &#175; &#177; s )</p><p>注：a，与对照组入院时相较，P &lt; 0.05；b，与冠心宁组入院时相较，P &lt; 0.05；#，与对照组治疗3个月后相较，P &lt; 0.05。</p></sec><sec id="s7_4"><title>3.4. 两组患者入院前、PCI术后、3个月后肾功能指标比较</title><p>对照组与冠心宁组入院前肾功能指标均无显著性差异(P &gt; 0.05)，PCI术后，两组患者肾功能下降(P &lt; 0.05)，但冠心宁组患者肾功能损害程度小于对照组(P &lt; 0.05)，治疗3个月后，两组肾功能指标均有改善(P &lt; 0.05)，且冠心宁组的改善程度优于对照组(P &lt; 0.01)，差异具有统计学意义。见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of renal function between the two groups before admission, after PCI and 3 months later ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  colspan="3"  >对照组(N = 40)</th><th align="center" valign="middle"  colspan="3"  >冠心宁组(N = 40)</th></tr></thead><tr><td align="center" valign="middle" >入院时</td><td align="center" valign="middle" >PCI术后</td><td align="center" valign="middle" >3个月后</td><td align="center" valign="middle" >入院时</td><td align="center" valign="middle" >PCI术后</td><td align="center" valign="middle" >3个月后</td></tr><tr><td align="center" valign="middle" >eGFR (ml/min)</td><td align="center" valign="middle" >81.72 &#177; 14.24</td><td align="center" valign="middle" >73.43 &#177; 15.56<sup>a</sup></td><td align="center" valign="middle" >80.36 &#177; 16.56<sup>c</sup></td><td align="center" valign="middle" >80.97 &#177; 14.45</td><td align="center" valign="middle" >77.05 &#177; 16.01<sup>b#</sup></td><td align="center" valign="middle" >83.74 &#177; 16.09<sup>d*</sup></td></tr><tr><td align="center" valign="middle" >SCr (μmol/L)</td><td align="center" valign="middle" >77.69 &#177; 19.17</td><td align="center" valign="middle" >88.72 &#177; 18.23<sup>a</sup></td><td align="center" valign="middle" >78.28 &#177; 15.34<sup>c</sup></td><td align="center" valign="middle" >78.52 &#177; 19.11</td><td align="center" valign="middle" >83.27 &#177; 17.98<sup>b#</sup></td><td align="center" valign="middle" >71.16 &#177; 13.22<sup>d*</sup></td></tr></tbody></table></table-wrap><p>表4. 两组入院前、PCI术后、3个月后肾功能指标比较( x &#175; &#177; s )</p><p>注：a，与对照组入院时相较，P &lt; 0.05；b，与冠心宁组入院时相较，P &lt; 0.05；c，与对照组术后相较，P &lt; 0.05；d，与冠心宁组术后相较，P &lt; 0.05；#，与对照组术后相较，P &lt; 0.05；*，与对照组治疗3个月后相较，P &lt; 0.01。</p></sec><sec id="s7_5"><title>3.5. 两组患者出院前、3个月后的心肺功能指标比较</title><p>对照组与冠心宁组治疗3个月后，6分钟步行距离、VO<sub>2</sub>max、AT、MET等心肺功能指标均有明显改善(P &lt; 0.05)，且冠心宁组的改善程度均优于对照组(P &lt; 0.01)，差异具有统计学意义。见表5。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Comparison of cardiopulmonary function between the two groups before discharge and 3 months after discharge ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  colspan="2"  >对照组(N = 40)</th><th align="center" valign="middle"  colspan="2"  >冠心宁组(N = 40)</th></tr></thead><tr><td align="center" valign="middle" >出院前</td><td align="center" valign="middle" >3个月后</td><td align="center" valign="middle" >出院前</td><td align="center" valign="middle" >3个月后</td></tr><tr><td align="center" valign="middle" >6分钟步行距离 (m)</td><td align="center" valign="middle" >265.23 &#177; 55.34</td><td align="center" valign="middle" >285.23 &#177; 57.23<sup>a</sup></td><td align="center" valign="middle" >268.34 &#177; 57.56</td><td align="center" valign="middle" >321.32 &#177; 62.21<sup>b*</sup></td></tr><tr><td align="center" valign="middle" >VO<sub>2</sub>max [mL/(min&#183;kg)]</td><td align="center" valign="middle" >20.56 &#177; 4.09</td><td align="center" valign="middle" >24.56 &#177; 4.20<sup>a</sup></td><td align="center" valign="middle" >20.45 &#177; 3.98</td><td align="center" valign="middle" >26.97 &#177; 3.21<sup>b*</sup></td></tr><tr><td align="center" valign="middle" >AT [mL/(min&#183;kg)]</td><td align="center" valign="middle" >15.52 &#177; 2.56</td><td align="center" valign="middle" >16.23 &#177; 3.51<sup>a</sup></td><td align="center" valign="middle" >15.98 &#177; 2.81</td><td align="center" valign="middle" >17.59 &#177; 3.89<sup>b*</sup></td></tr><tr><td align="center" valign="middle" >MET [mL/(min&#183;kg)]</td><td align="center" valign="middle" >3.12 &#177; 0.87</td><td align="center" valign="middle" >3.45 &#177; 0.91<sup>a</sup></td><td align="center" valign="middle" >3.23 &#177; 0.89</td><td align="center" valign="middle" >3.53 &#177; 0.94<sup>b*</sup></td></tr></tbody></table></table-wrap><p>表5. 两组患者出院前、3个月后的心肺功能指标比较( x &#175; &#177; s )</p><p>注：a，与对照组出院前相较，P &lt; 0.05；b，与冠心宁组出院前相较，P &lt; 0.05；*，与对照组治疗3个月后相较，P &lt; 0.01。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>急性冠脉综合征是以冠状动脉内不稳定的粥样斑块破裂或糜烂，继发完全或不完全管腔闭塞性血栓形成为病理基础的一组心脏急性缺血综合征。中医认为，冠心病心绞痛属“胸痹”和“心痛”范畴，治疗以健脾化痰、活血化瘀、舒肝理气为主 [<xref ref-type="bibr" rid="hanspub.41826-ref7">7</xref>]。冠心宁片其主要成分为由丹参和川芎，具有活血化瘀，通脉养心之效，在冠心病稳定性心绞痛治疗中疗效显著 [<xref ref-type="bibr" rid="hanspub.41826-ref8">8</xref>]。现代药理学研究证实，川芎具有减少冠脉微血栓形成、改善内皮功能、抗血小板、抗炎和保护受损心肌的作用，丹参具有抗炎、抗动脉硬化，可以有效减缓心率，控制凝血，促进冠脉侧支循环，改善心脏功能以及扩张冠状动脉等作用，两种有效成分互相促进，可同时抑制血小板聚集及炎症激活，促使斑块稳定，减少冠心病事件。</p><p>本文结果显示，冠心宁组患者在联合用药之后，患者住院期间心律失常、心绞痛等不良心血管事件发生频率明显低于对照组(P &lt; 0.05)，证实冠心宁片可以有效减少不稳定型心绞痛患者不良心血管事件的发生。hs-CRP是机体受到微生物入侵或组织损伤等炎症性刺激是肝细胞合成的急性项蛋白，是炎性标志物 [<xref ref-type="bibr" rid="hanspub.41826-ref9">9</xref>]。同时，hs-CRP也可以作为参与冠状动脉的粥样硬化及其斑块产生和破裂的重要介质 [<xref ref-type="bibr" rid="hanspub.41826-ref10">10</xref>]。观察结果显示，在常规治疗基础上，加用冠心宁片的患者PCI术后及随访3个月后的血清hs-CRP低于对照组(P &lt; 0.05)，此外两组PCI术后及3个月后的LVEF、CK-MB、cTnT及BNP等反应心脏功能的指标均得到一定改善(P &lt; 0.05)，冠心宁组改善程度明显优于对照组(P &lt; 0.05)，提示冠心宁可抑制炎症反应，降低炎症因子含量，保护血管内皮形态和功能，稳定粥样斑块，有效改善心脏功能。本研究还表明，与对照组相比，冠心宁组患者PCI术后肾功能受损程度较小(P &lt; 0.05)，术后3个月后的肾功能得到更为明显的改善(P &lt; 0.01)，提示冠心宁除改善心功能外，还可一定程度上改善肾功能。这可能与冠心宁有助于改善肾脏组织的血液循环、降低氧化应激和炎症反应等作用相关。</p><p>心肺运动试验对心血管、呼吸系统进行非侵入性同时测量，整合心肺功能，从而精确评估个体的心肺储备能力、有氧代谢能力，常用的观察指标包括VO<sub>2</sub>max、AT及MET。6分钟步行试验及心肺运动试验结果显示，患者随访3个月后的6分钟步行距离、VO<sub>2</sub>max、AT及MET等指标较出院前有明显改善(P &lt; 0.05)，且冠心宁组改善效果较对照组明显(P &lt; 0.01)，说明冠心宁片可以综合改善心脏、肺功能和运动耐量。</p></sec><sec id="s9"><title>5. 小结与展望</title><p>综上，本项目研究发现，冠心宁片干预有助于：1) 减少不稳定型心绞痛患者心绞痛、心律失常等不良心血管事件的发生；2) 改善LVEF、6分钟步行距离、VO<sub>2</sub>max、AT及MET等指标，提高患者的心肺运动功能；3) 改善肾功能，降低PCI术后对比剂带来的肾功能损害；4) 降低CK-MB、cTnT、hs-CRP等，改善机体炎症反应。项目研究结果提示，冠心宁的上述保护作用可能是通过改善组织的血液循环、降低氧化应激和炎症反应等机制而实现的。项目的完成进一步丰富了冠心宁片在心、肺、肾脏保护方面的理论依据，探索了中西医结合治疗的新方法，有助于提高患者的疾病预后和生活质量，具有重要的临床应用和推广价值。</p><p>本项目虽较为粗浅地探索了冠心宁对不稳定型心绞痛患者PCI治疗后心、肺、肾功能的改善作用及潜在机制，取得了初步的阳性结果，但研究尚需不断深入。冠心宁发挥上述作用的机制有待进一步挖掘，其作用的主要有效成分、有效单体、涉及的分子靶点和信号通路等，均亟待后续研究去探索。</p></sec><sec id="s10"><title>基金项目</title><p>浙江省医学会临床科研资金项目(2018ZYC-A104)。</p></sec><sec id="s11"><title>文章引用</title><p>唐伟良,郑招海,张 鹏,沈 静,周 妍,彭 放. 冠心宁对不稳定型心绞痛患者心肺功能保护作用的研究Study on the Protective Effect of Guanxinning on the Cardiopulmonary Function of Patients with Unstable Angina Pectoris[J]. 临床医学进展, 2021, 11(04): 1157-1163. https://doi.org/10.12677/ACM.2021.114257</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41826-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">高文君, 韩明华. 急性冠脉综合征预后的预测研究进展[J]. 心血管病学进展, 2018, 39(4): 606-610.</mixed-citation></ref><ref id="hanspub.41826-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">阮鸣, 孔令义, 罗建光. 冠心宁注射液的化学成分研究[J]. 中草药, 2014, 45(13): 1838-1844.</mixed-citation></ref><ref id="hanspub.41826-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">李丹, 王俊文, 李彦文, 等. 冠心宁注射液临床应用及不良反应的文献回顾分析[J]. 药物评价研究, 2016, 39(1): 116-121.</mixed-citation></ref><ref id="hanspub.41826-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">严春琳, 杨静, 韩际宏, 等. 中药抗动脉粥样硬化机制研究进展[J]. 中国药理学与毒理学杂志, 2014, 28(6): 904-913.</mixed-citation></ref><ref id="hanspub.41826-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">乔凤仙, 蔡皓, 屠鹏飞, 等. 单标多组分HPLC定量分析法在川芎质量评价中的应用[J]. 药学学报, 2015, 50(6): 749-754.</mixed-citation></ref><ref id="hanspub.41826-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">王博龙, 刘志强. 计算机模拟研究冠心宁注射液主要成分治疗心血管疾病的网络药理学机制[J]. 中草药, 2018, 49(14): 3357-3368.</mixed-citation></ref><ref id="hanspub.41826-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">卫靖靖, 朱明军, 于瑞, 等. 中医论治冠心病的研究进展[J]. 中医研究, 2020, 33(10): 74-77.</mixed-citation></ref><ref id="hanspub.41826-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">吴宇. 冠心宁片联合西药治疗冠心病稳定型心绞痛55例疗效观察[J]. 浙江中医杂志, 2019, 54(10): 753-754.</mixed-citation></ref><ref id="hanspub.41826-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">罗玮, 崔博, 刘志勇, 等. 不稳定型心绞痛患者甲状腺功能及高敏C-反应蛋白水平与冠状动脉狭窄程度的相关性[J]. 中国老年学杂志, 2012, 32(16): 3391-3393.</mixed-citation></ref><ref id="hanspub.41826-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Libby, P. (2002) Inflammation in Atherosclerosis. Nature, 420, 868-874. &lt;br&gt;https://doi.org/10.1038/nature01323</mixed-citation></ref></ref-list></back></article>